Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

Lifevantage Corporation is a health and nutrition company that develops dietary supplements. The Company produces nutritional products that are intended to combat oxidative stress to support brain, eye, and joint function, as well as skin canine products.

<ul><li>LFVN reports its 4QFY24 results on Wednesday, August 28, after market close. </li><li>We are not changing our forecasts. Our detailed earnings models are below.</li><li>We are looking for recent trends to continue. Sales have been challenged all year, with the company bringing down its FY24 sales outlook as the fiscal year progressed, while keeping its adjusted EBITDA forecast the same, as margins have been better than originally expected.</li></ul>

LFVN reports its 4QFY24 results on Wednesday, August 28, after market close. We are not changing our forecasts. Our detailed earnings models are below.We are looking for recent trends to continue. Sales have been challenged all year, with the company bringing down its FY24 sales outlook as the fiscal year progressed, while keeping its adjusted EBITDA forecast the same, as margins have been better than originally expected.

LifeVantage Corporation - (LFVN) 4QFY24 Results Due Next Week

Thematic (Sector/Industry)

<ul><li>The WTR Sustainable Index was up 3.0% W/W versus the S&amp;P 500 Index (up 3.9%), the Russell 2000 Index (up 2.9%) and the Nasdaq Index (up 5.4%).</li><li>Energy Technology (13.8% of the index) was up 3.8%, while Industrial Climate and Ag Technology (46.2% of the index) was up 2.9%, ClimateTech Mining was up 2.7%, and Advanced Transportation Solutions (20.1% of index) was up 2.7%.</li><li>Top 10 Performers: ZEV, ORGN, GIGA, GTEC, PSIX, GEVO, GCEI, COMM, ASPN, FF</li></ul>

The WTR Sustainable Index was up 3.0% W/W versus the S&amp;P 500 Index (up 3.9%), the Russell 2000 Index (up 2.9%) and the Nasdaq Index (up 5.4%).Energy Technology (13.8% of the index) was up 3.8%, while Industrial Climate and Ag Technology (46.2% of the index) was up 2.9%, ClimateTech Mining was up 2.7%, and Advanced Transportation Solutions (20.1% of index) was up 2.7%.Top 10 Performers: ZEV, ORGN, GIGA, GTEC, PSIX, GEVO, GCEI, COMM, ASPN, FF

Sustainable Investing Surveyor - Focus on Green Plains, Inc. (GPRE)

Ainos, Inc. is a diversified healthcare company. The Company engages in the discovery and development of novel biopharmaceuticals, technologically medical treatments, and consumer products, as well as provides treatments of neoplastic, viral, and autoimmune diseases. Ainos operates in the United States and Taiwan.

<ul>
<li>Advancing AI Nose beyond healthcare into smart manufacturing.</li>
<li>Ainos announced initial results from a VOC sensing program in industrial safety and smart manufacturing with its Japanese co-development partners.</li>
<li>As of August 15, 2024, AI Nose achieved 79% accuracy in detecting 22 different VOCs to identify 761 samples of potentially hazardous gases or contaminants. </li>
</ul>


Advancing AI Nose beyond healthcare into smart manufacturing.
Ainos announced initial results from a VOC sensing program in industrial safety and smart manufacturing with its Japanese co-development partners.
As of August 15, 2024, AI Nose achieved 79% accuracy in detecting 22 different VOCs to identify 761 samples of potentially hazardous gases or contaminants. 


Ainos, Inc.( AIMD): AI Nose Expanding into Industrial Smart Manufacturing

Gevo Inc. operates as a technology development company for biobutanol. The Company offers products that enable the production of fuels for the diesel and jet markets, and the production of green chemicals derived from renewable resources.

<ul><li>Gevo produces renewable fuels and develops related technologies that help customers meet carbon abatement goals as cost effectively as possible.</li><li>Gevo is pursuing several complementary businesses, each at a different stage in the business cycle, including sustainable aviation fuel (SAF) (Net- Zero 1 [NZ1]) (near FID), carbon tracking (Verity) (near revenue), renewable natural gas (RNG) (operating), bio- propylene (pilot phase joint development agreement [JDA] with LG Chem), and other businesses.</li></ul>

Gevo produces renewable fuels and develops related technologies that help customers meet carbon abatement goals as cost effectively as possible.Gevo is pursuing several complementary businesses, each at a different stage in the business cycle, including sustainable aviation fuel (SAF) (Net- Zero 1 [NZ1]) (near FID), carbon tracking (Verity) (near revenue), renewable natural gas (RNG) (operating), bio- propylene (pilot phase joint development agreement [JDA] with LG Chem), and other businesses.

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, Medicare posted the first negotiated prices for Part D drugs, an additional 11% discount by our estimate.</li><li>Mpox declared a global emergency, as the SIGA antipox treatment drug failed study, but mpox vaccine makers BVNRY and GOVX got a boost. </li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, Medicare posted the first negotiated prices for Part D drugs, an additional 11% discount by our estimate.Mpox declared a global emergency, as the SIGA antipox treatment drug failed study, but mpox vaccine makers BVNRY and GOVX got a boost. 

Biopharma Week in Review - August 19, 2024